Trial Profile
A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Nov 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 28 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.